Tag Archives: BCRX

Top 5 Low Price Stocks To Own Right Now

I recently stumbled on a snippet of DA Davidson’s research on Roku (ROKU). The research analyst had a price target of $30 before bumping it to $32 after Q1 earnings. The bearish price target is in line with many other bears (i.e. Morgan Stanely, Citi, etc.); however, the method through which the analyst arrived at the $30 price target looks very wrong.

Instead of using simple near-term multiples to justify a low price target (as is the case with the Morgan Stanley analyst), the analyst used a discounted cash flow model. It is the right approach as a DCF model allows an investor to appreciate a company’s long-term potential. However, I can’t seem to reconcile his assumptions with a probable outcome in the real world.

Source: benzinga.com

Top 5 Low Price Stocks To Own Right Now: Martin Midstream Partners L.P.(MMLP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    ONEOK (NYSE:OKE) has made several shrewd moves over the past few years, which have positioned it to grow its high-yielding dividend at a high rate. One of the latest is its recent deal to buy out Martin Midstream Partners’ (NASDAQ:MMLP) 20% interest in the West Texas LPG pipeline system. With full control of that pipeline, the company can more aggressively pursue expansion opportunities, which recently led it to secure a second project on the system that positions it for even more growth in the future.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Martin Midstream Partners (MMLP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Martin Midstream Partners (MMLP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Matthew DiLallo]

    Master limited partnerships (MLPs) Buckeye Partners (NYSE:BPL) and Martin Midstream Partners (NASDAQ:MMLP) currently yield a jaw-dropping 13.7% and 17.4%, respectively. Both payouts are well above the 8% average yield of MLPs held in the Alerian MLP Index, which is a clear sign that the market doesn’t believe in the long-term viability of these payouts. Their unsustainability is even more apparent when we look at the embarrassingly weak financial profiles currently backing these payouts, which is why investors should steer clear of these high-yield stocks.

  • [By Joseph Griffin]

    Martin Midstream Partners L.P. (NASDAQ:MMLP) – Equities research analysts at Capital One Financial lowered their FY2018 earnings per share estimates for shares of Martin Midstream Partners in a report released on Thursday, February 14th. Capital One Financial analyst K. May now forecasts that the pipeline company will earn $0.12 per share for the year, down from their previous estimate of $0.14. Capital One Financial also issued estimates for Martin Midstream Partners’ Q4 2018 earnings at $0.22 EPS and FY2020 earnings at $0.82 EPS.

Top 5 Low Price Stocks To Own Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Maxx Chatsko]

    Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) rose over 21% last month, according to data provided by S&P Global Market Intelligence. In the beginning of the month, the company announced the successful sale of 10.4 million shares that raised around $57.5 million in gross proceeds.

Top 5 Low Price Stocks To Own Right Now: First Cash Financial Services, Inc.(FCFS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on FirstCash (FCFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on FirstCash (FCFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    First Cash Financial Services (NYSE: FCFS) and Ferrellgas Partners (NYSE:FGP) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

  • [By Logan Wallace]

    First Cash Financial Services, Inc. (NYSE:FCFS) shares hit a new 52-week high and low during trading on Thursday . The company traded as low as $88.95 and last traded at $88.70, with a volume of 371494 shares traded. The stock had previously closed at $87.80.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on First Cash Financial Services (FCFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    FirstCash Inc (NYSE:FCFS) has been assigned an average rating of “Hold” from the eight research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $95.75.

Top 5 Low Price Stocks To Own Right Now: TechTarget, Inc.(TTGT)

Advisors’ Opinion:

  • [By Max Byerly]

    TechTarget (NASDAQ:TTGT) and DHI Group (NYSE:DHX) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on TechTarget (TTGT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    1. TechTarget (Nasdaq: TTGT)
    This $500 million-plus cloud-based content marketing company has soared over 40% this year. What triggered the surge is the company finally began to produce solid earnings after years trying to get traction. Guidance has also dramatically improved this year creating excitement for investors.

Top 5 Low Price Stocks To Own Right Now: Newmont Mining Corporation(NEM)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Public Employees Retirement Association of Colorado reduced its stake in Newmont Mining Co. (NYSE:NEM) by 4.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 92,218 shares of the basic materials company’s stock after selling 4,795 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Newmont Mining were worth $3,603,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Scott Levine]

    In one of the gold industry’s most notable news stories last month, Goldcorp announced that it had entered into a definitive agreement with Newmont Mining (NYSE:NEM) in which Newmont will acquire all outstanding shares of Goldcorp’s common stock in a deal valued at $10 billion. Newmont will acquire each Goldcorp share for 0.3280 of a Newmont share, representing a 17% premium based on the companies’ 20-day volume weighted average share prices. The transaction is expected to close in the second quarter of 2019 and has already been approved by both companies’ boards of directors.

  • [By Joseph Griffin]

    Boston Partners boosted its holdings in shares of Newmont Mining Co. (NYSE:NEM) by 4.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,976 shares of the basic materials company’s stock after buying an additional 2,033 shares during the quarter. Boston Partners’ holdings in Newmont Mining were worth $1,992,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Wilkins Investment Counsel Inc. lifted its stake in Newmont Mining Co. (NYSE:NEM) by 0.7% in the 1st quarter, Holdings Channel reports. The firm owned 359,285 shares of the basic materials company’s stock after acquiring an additional 2,550 shares during the period. Newmont Mining comprises about 4.4% of Wilkins Investment Counsel Inc.’s holdings, making the stock its 2nd biggest position. Wilkins Investment Counsel Inc.’s holdings in Newmont Mining were worth $14,037,000 at the end of the most recent reporting period.

Top 5 Low Price Stocks For 2019

Walmart, already the nation’s largest retailer, is trying to create a massive, digital marketplace to draw more shoppers to its website — and away from its biggest rival, Amazon.

Starting Monday, edgy outdoor-gear company Moosejaw will be featured on Walmart’s website with its own, online destination. Purchased by Walmart in 2017, Moosejaw’s assortment of merchandise includes items from brands like Patagonia and Canada Goose — a departure from what many customers have come to expect from Walmart and its everyday low prices.

The Bentonville, Arkansas-based retailer has been branching into higher-end goods. It’s acquired men’s apparel company Bonobos and women’s fashion and accessories company ModCloth in recent years. Moosejaw’s online shop also builds on Walmart’s recent deal with Lord & Taylor, which created a fashion destination on Walmart.com with more premium brands.

Top 5 Low Price Stocks For 2019: SK TELECOM ADR EACH REP 1/9 KRW500(CIT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Here are some of the news articles that may have effected Accern’s analysis:

    Get CIT Group alerts:

    We’re winning the war on CIT heists, say police (citizen.co.za) Oppenheimer Equities Analysts Reduce Earnings Estimates for CIT Group (CIT) (americanbankingnews.com) Did Grandview police use their crisis training before fatally shooting man with sword? (kansascity.com) CIT Group (CIT) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com) CIT Adds New Executive to Communications & Technology Finance Team (abladvisor.com)

    Shares of CIT Group traded up $0.66, reaching $51.56, during midday trading on Friday, according to Marketbeat.com. The stock had a trading volume of 37,528 shares, compared to its average volume of 1,228,943. CIT Group has a one year low of $43.25 and a one year high of $56.14. The company has a market cap of $6.42 billion, a PE ratio of 16.76, a price-to-earnings-growth ratio of 1.27 and a beta of 1.28. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.09 and a quick ratio of 1.09.

  • [By Joseph Griffin]

    Traders sold shares of CIT Group (NYSE:CIT) on strength during trading on Friday. $12.27 million flowed into the stock on the tick-up and $45.80 million flowed out of the stock on the tick-down, for a money net flow of $33.53 million out of the stock. Of all companies tracked, CIT Group had the 0th highest net out-flow for the day. CIT Group traded up $0.38 for the day and closed at $50.31

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on CIT Group (CIT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    These are some of the news headlines that may have effected Accern Sentiment’s rankings:

    Get CIT Group alerts:

    CIT Closes on $26.6MM Loan for Medical Buildings (abladvisor.com) CIT provides $26.6 mln to joint venture to buy medical buildings (pehub.com) As security companies and guards face off, a wave of crime hits cash vans (msn.com) CIT Announces Addition to Rail Division’s Senior Leadership Team (finance.yahoo.com) CIT Group (CIT) EVP Sells $90,791.60 in Stock (americanbankingnews.com)

    A number of equities research analysts have issued reports on the company. TheStreet downgraded CIT Group from a “b-” rating to a “c+” rating in a research note on Thursday, June 14th. BTIG Research restated a “buy” rating and set a $57.00 price target on shares of CIT Group in a research note on Wednesday, April 18th. ValuEngine downgraded CIT Group from a “buy” rating to a “hold” rating in a research note on Thursday, May 3rd. Zacks Investment Research downgraded CIT Group from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, BMO Capital Markets cut their price target on CIT Group from $49.00 to $46.00 and set a “market perform” rating for the company in a research note on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $54.83.

Top 5 Low Price Stocks For 2019: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Shares of Idera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharma focused on oncology and rare diseases, fell 16% as of 2:20 p.m. EDT on Wednesday after its proposed merger with BioCryst Pharmaceuticals (NASDAQ:BCRX) was called off. Shares of BioCryst were up about 1% on the news. 

  • [By Cory Renauer]

    Idera Pharmaceuticals shares slid further when management announced an attempt to merge with BioCryst Pharmaceuticals (NASDAQ:BCRX) earlier this year. BioCryst shareholders vehemently opposed the merger, which has investors feeling extra skeptical about tilsotolimod’s potential.

  • [By Logan Wallace]

    BidaskClub upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares fell on Tuesday after the company announced initial results from its hereditary angioedema (HAE) trial.

  • [By Steve Symington]

    Shares of Idera Pharmaceuticals fell 20.4% after the biotech company announced the termination of its planned merger with BioCryst Pharmaceuticals (NASDAQ:BCRX). 

Top 5 Low Price Stocks For 2019: Cinemark Holdings Inc(CNK)

Advisors’ Opinion:

  • [By Rich Duprey]

    Movie theater chains are testing their own services, too. AMC Entertainment (NYSE:AMC) has launched Stubs A-List, offering three movies per week for $19.95 per month. Cinemark’s (NYSE:CNK) Movie Club offers one ticket per month for $8.99, but throws in 20% discounts on concessions (additional tickets can be purchased for $8.99 as well).

  • [By Rich Smith]

    On balance, AMC’s offer still appears to fall significantly short of MoviePass’ as a value proposition (as did an earlier competing offer from Cinemark (NYSE:CNK) last year). So long as MoviePass remains in business, I honestly can’t see many moviegoers taking AMC up on its offer.

  • [By Rich Duprey]

    Other services are trying different options. Cinemark Holdings (NYSE:CNK) charges $8.99 for one movie a month through its Movie Club service, but also offers 20% concession stand discounts. Sinemia is going with one movie per day for $29.95 per month, though other plans are available at different price points.

  • [By Motley Fool Staff]

    Vincent Shen: One of the theater chains that we talked about on this similar show last year is no longer in the running as a public company in terms of the stocks. First, with Cinemark (NYSE:CNK), one of the two large remaining chains, it has an offering called Movie Club. This launched last year. $8.99 per month. What you get is one 2D ticket that rolls over if it’s unused. You can build those rollover tickets if you don’t go that often. Plus, 20% off concessions, and there’s no online fees for when you buy those tickets. Then, you can get up to two additional add-on tickets for $8.99 each.

Top 5 Low Price Stocks For 2019: Globalstar Inc.(GSAT)

Advisors’ Opinion:

  • [By Paul Ausick]

    Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 6% Tuesday and posted a new 52-week low of $0.47 after closing Monday at $0.50. The stock’s 52-week high is $2.30. Volume totaled about 4.3 million, about 20% below the daily average of around  5.4 million. The company had no specific news.

  • [By Paul Ausick]

    Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 12.5% Tuesday and posted a new 52-week low of $0.77 after closing Monday at $0.88. The stock’s 52-week high is $2.59. Volume was about 70% above the daily average of around 3.7 million shares. The had no specific news.

  • [By Lisa Levin]

    Thursday morning, the telecommunication services shares rose 1.06 percent. Meanwhile, top gainers in the sector included Globalstar, Inc. (NYSE: GSAT), up 5 percent, and Partner Communications Company Ltd. (NASDAQ: PTNR) up 4 percent.

Top 5 Low Price Stocks For 2019: InterOil Corporation(IOC)

Advisors’ Opinion:

  • [By Shane Hupp]

    I/O Coin (CURRENCY:IOC) traded 26.1% higher against the US dollar during the one day period ending at 22:00 PM E.T. on August 17th. Over the last seven days, I/O Coin has traded up 50% against the US dollar. One I/O Coin coin can now be purchased for $0.39 or 0.00005901 BTC on exchanges. I/O Coin has a market capitalization of $6.55 million and approximately $14,268.00 worth of I/O Coin was traded on exchanges in the last day.

  • [By Stephan Byrd]

    Media headlines about InterOil (NYSE:IOC) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. InterOil earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news articles about the oil and gas company an impact score of 45.5148763796823 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Top 10 High Tech Stocks To Invest In 2019

Chipotle Mexican Grill (CMG ) has suffered in the public eye and stock market after several food-related illnesses affected consumers. Of these, an E.coli outbreak in 2015 and norovirus outbreak in 2017, caught the eye of customers and had drastic financial consequences.

A 30% loss in sales occurred following the initial outbreak, and the stock has fallen to less than half of its highest valuation since then. The company’s current earnings outlook does not look bright either. With 100% negative agreement among revising analysts, we have seen three adjustments to the company’s full-year EPS estimates within the past 60 days.

Despite all of this, the stock seems to be pushing back today. Chipotle Mexican Grill shares rose $7.84, or 2.4%, since yesterday’s close at $326.60. Why is this the case? The root is managerial transitions.

Following the incidents described above, the company restructured its leadership. In February, Chipotle announced that Steve Ells would step down as the company’s chief executive and be replaced by former Yum! Brands executive Brian Niccol. The stock rose 11% in after-hours trading that day.

Top 10 High Tech Stocks To Invest In 2019: Lydall, Inc.(LDL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Lydall (LDL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 High Tech Stocks To Invest In 2019: Seadrill Limited(SDRL)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Thursday, the energy shares rose 1.34 percent. Meanwhile, top gainers in the sector included Seadrill Limited (NYSE: SDRL), up 46 percent, and Sanchez Energy Corporation (NYSE: SN) up 8 percent.

  • [By Garrett Baldwin]

    Markets have been under pressure once again by the U.S. Federal Reserve. Inflation levels are going through the roof… but the people in charge of managing it have been lying to Americans for years. Now it’s time to get even.Money MorningLiquidity Specialist Lee Adler has the perfect way to make a lot of money when no one is looking.Read it here.

    The Top Stock Market Stories for Wednesday
    In addition to Trump’s concerns about China and trade, the President also stated that he is unsure whether a summit with North Korean leader Kim Jong-Un will take place as planned. Multiple media outlets this morning are questioning if the event will take place. The summit is tentatively planned for June 12. Banking stocks were on the move after Congress passed new laws designed to reduce regulations for thousands of financial institutions. The new rules will ensure that smaller banks are not facing the same strict rules as the bigger giants. The financial sector has been lobbying to changes to the Dodd-Frank Act since its inception after the 2008-09 financial crisis. Facebook Inc. (Nasdaq: FB) CEO Mark Zuckerberg met with members of the European Union on Tuesday. The CEO of the social media giant outraged European Parliament members after reportedly dodging questions about user privacy and the firm’s collection of personal data. During the conversation, EU members questioned whether Facebook is a monopoly and pondered if the firm should be broken up due to antitrust concerns.
    Three Stocks to Watch Today: TGT, LOW, TIF
    Shares of Target Corporation (NYSE: TGT) fell nearly 6% after the retail giant fell short of earnings expectations before the bell. The firm reported earnings per share of $1.32. This figure missed Wall Street earnings expectations by six cents. The retail giant blamed poor spring weather for its performance and said that its bottom line has been impacted by the costs of upgrading its physical locations. Lowe’s Companies (NYSE: LOW) stock gained

  • [By Lisa Levin]

    Wednesday morning, the energy shares climbed 1.29 percent. Meanwhile, top gainers in the sector included SeaDrill Limited (NYSE: SDRL), up 19 percent, and Energy XXI Gulf Coast, Inc. (NASDAQ: EGC), up 10 percent.

Top 10 High Tech Stocks To Invest In 2019: A V Homes, Inc.(AVHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    World Fuel Services Corporation (NYSE: INT) tumbled 18 percent to $22.90 following Q1 results.
    Biglari Holdings Inc. (NYSE: BH) fell 17.4 percent to $349.52. Washington Prime Group will replace Biglari Holdings in the S&P SmallCap 600 on Tuesday, May 1.
    Flex Ltd. (NASDAQ: FLEX) dipped 15.7 percent to $14.03 after a mixed fourth quarter report.
    FormFactor, Inc. (NASDAQ: FORM) fell 15.3 percent to $11.65. FormFactor is expected to release Q1 results on May 2.
    Data I/O Corporation (NASDAQ: DAIO) dropped 14.3 percent to $6.24 following Q1 results.
    National Instruments Corporation (NASDAQ: NATI) fell 14.3 percent to $ 42.34 after reporting Q1 results.
    United States Steel Corporation (NYSE: X) dipped 14.2 percent to $32.37 following Q1 results.
    Civeo Corporation (NYSE: CVEO) dropped 13.5 percent to $3.33. Civeo posted a Q1 loss of $0.42 per share on sales of $101.504 million.
    athenahealth, Inc. (NASDAQ: ATHN) fell 12.4 percent to $125.310 after reporting Q1 results.
    Charter Communications, Inc. (NASDAQ: CHTR) shares tumbled 12.1 percent to $262.06 as the company posted Q1 results.
    Value Line, Inc. (NASDAQ: VALU) fell 11.3 percent to $19.10.
    Federated Investors, Inc. (NYSE: FII) shares dropped 11.2 percent to $27.605 after the company posted downbeat quarterly earnings.
    AV Homes, Inc. (NASDAQ: AVHI) declined 10.7 percent to $17.20 following Q1 results.
    CalAmp Corp. (NASDAQ: CAMP) dropped 9.4 percent to $21.01 after reporting Q4 results.
    Tandem Diabetes Care, Inc. (NASDAQ: TNDM) shares fell 8.9 percent to $7.280 following mixed Q1 results.
    Sony Corporation (NYSE: SNE) shares fell 8.4 percent to $45.97 after reporting Q4 results.
    LogMeIn Inc (NASDAQ: LOGM) fell 8.2 percent to $109.825. LogMeIn reported upbeat earnings for its first quarter, but issued weak second quarter and FY18 earning guidance.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO

Top 10 High Tech Stocks To Invest In 2019: iAnthus Capital Holdings, Inc. (ITHUF)

Advisors’ Opinion:

  • [By Spencer Israel]

    The charts below are courtesy of VantagePoint, a platform that uses Artificial Intelligence and machine learning to forecast future price movements 1-3 days in advance with up to 86 percent accuracy. The blue line represents a predictive moving average that shows what’s going to happen three days in advance, and the black line is a simple 10-day moving average. A crossover of the blue line over the black line indicates a bullish signal from the software, and vice versa for a bearish signal.

    iAthus Capital Holdings, Inc. (OTC: ITHUF)

    Up 94 percent YTD

  • [By Javier Hasse]

    Licensed cannabis production facilities owner and operator iAnthus Capital Holdings Inc (OTC: ITHUF) announced a $50 million investment from Gotham Green Partners. Management believes this is the largest investment to date by a single investor in a publicly traded U.S. cannabis operating company. iAnthus plans to allocate the proceeds of this financing to repay a $20 million one-year note and accrued interest to VCP Bridge LLC; continue to build out cultivation facilities and dispensaries in the New York and Florida markets; and, potentially, to expand activities. The remaining expenditures for completing iAnthus’ Massachusetts and Vermont operations will be funded with current cash on hand, management assured.

  • [By ]

    Much of the focus of cannabis investors has been centered on Canada and California. This makes sense given that they are the two largest recreational (or soon to be) cannabis markets in the world. However, one publicly traded company with US-centric cannabis operations has taken a different approach. iAnthus Capital is listed in Canada on the CSE (OTCQB:ITHUF), but is headquartered in New York and incorporated in Delaware. Unlike other Canadian-listed cannabis companies, most of which are aiming to get in on the highly competitive green-rush in California and Canada, iAnthus has set its sights on becoming the dominant player on the U.S. East Coast.

Top 10 High Tech Stocks To Invest In 2019: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 High Tech Stocks To Invest In 2019: Fisher(j)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Joincoin (CURRENCY:J) traded 1.7% lower against the U.S. dollar during the 24 hour period ending at 0:00 AM ET on May 8th. Joincoin has a total market cap of $145,714.00 and $7.00 worth of Joincoin was traded on exchanges in the last 24 hours. During the last week, Joincoin has traded up 28.6% against the U.S. dollar. One Joincoin coin can currently be bought for about $0.0471 or 0.00000521 BTC on cryptocurrency exchanges.

Top 10 High Tech Stocks To Invest In 2019: JinkoSolar Holding Company Limited(JKS)

Advisors’ Opinion:

  • [By Dustin Parrett]

    One of the best ways to play it is by owning the top Chinese solar stock, Jinko Solar Holding Company Ltd. (NYSE: JKS).

    It’s already the world’s third-largest supplier of photovoltaic cells – an essential component of solar panels. Plus, it’s plugged right into China’s skyrocketing solar industry.

Top 10 High Tech Stocks To Invest In 2019: Brady Corporation(BRC)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Best Buy Co., Inc. (NYSE: BBY) is projected to report quarterly earnings at $0.74 per share on revenue of $8.73 billion.
    McKesson Corporation (NYSE: MCK) is expected to report quarterly earnings at $3.56 per share on revenue of $51.25 billion.
    Medtronic plc (NYSE: MDT) is estimated to report quarterly earnings at $1.39 per share on revenue of $8.00 billion.
    Hormel Foods Corporation (NYSE: HRL) is projected to report quarterly earnings at $0.45 per share on revenue of $2.39 billion.
    Brady Corporation (NYSE: BRC) is expected to report quarterly earnings at $0.49 per share on revenue of $291.47 million.
    Sanderson Farms, Inc. (NASDAQ: SAFM) is projected to report quarterly earnings at $2.2 per share on revenue of $841.75 million.
    The Toronto-Dominion Bank (NYSE: TD) is estimated to report quarterly earnings at $1.16 per share on revenue of $6.86 billion.
    Royal Bank of Canada (NYSE: RY) is expected to report quarterly earnings at $1.61 per share on revenue of $8.05 billion.
    58.com Inc. (NYSE: WUBA) is projected to report quarterly earnings at $0.21 per share on revenue of $372.49 million.
    Luxoft Holding, Inc. (NYSE: LXFT) is estimated to report quarterly earnings at $0.59 per share on revenue of $228.53 million.
    The Toro Company (NYSE: TTC) is expected to report quarterly earnings at $1.21 per share on revenue of $916.73 million.
    StealthGas Inc. (NASDAQ: GASS) is projected to report quarterly earnings at $0.06 per share on revenue of $37.75 million.
    Stage Stores, Inc. (NYSE: SSI) is estimated to report earnings for its first quarter.
    Thermon Group Holdings, Inc. (NYSE: THR) is projected to report quarterly earnings at $0.2 per share on revenue of $96.24 million.
    Tuniu Corporation (NASDAQ: TOUR) is estimated to report quarterly loss at $0.03 per share on revenue of $76.72 million.

     

Top 10 High Tech Stocks To Invest In 2019: Tile Shop Hldgs, Inc.(TTS)

Advisors’ Opinion:

  • [By Jason Hall]

    On the surface, there doesn’t seem to be much good inTile Shop Holdings Inc’s(NASDAQ:TTS) first-quarter earnings report. Sales fell 1% on a big 6.8% decline in comparable-store sales, earnings per share fell 47%, and expenses increased at double-digit rate. Surprisingly, Tile Shop’s shares traded up as much as 7% and finished the day of its earnings release up 5%.

  • [By Paul Ausick]

    Tile Shop Holdings Inc. (NASDAQ: TTS) dropped more than 31% Wednesday to post a new 52-week low of $5.80. Shares closed at $8.45 on Tuesday and the stock’s 52-week high is $22.40. Volume was around 6.3 million, about eight times the daily average of about 780,000. The company reported a quarterly loss this morning.

  • [By Lisa Levin]

    Shares of Tile Shop Holdings, Inc. (NASDAQ: TTS) got a boost, shooting up 9 percent to $6.20 after the company posted upbeat quarterly earnings.

    Sientra, Inc. (NASDAQ: SIEN) shares were also up, gaining 9 percent to $12.03 following the announcement of FDA approval for PMA supplement.

Top 10 High Tech Stocks To Invest In 2019: Xerox Corporation(XRX)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    Pressure from investors may trigger the sale of Xerox Corp. (NYSE: XRX). According to The Wall Street Journal:

    Xerox Corp.s first- and third-biggest investors, billionaires Carl Icahn and Darwin Deason, have formed an alliance and plan to encourage the printer and copier giant to explore a potential sale, according to people familiar with the matter.

  • [By Douglas A. McIntyre]

    Two corporate raiders have managed to kill a business combination between Xerox Corp. (NYSE: XRX) and an arm of Japanese company Fujifilm. It leaves troubled Xerox with a difficult future, after years of efforts by a string of executives to turn around its business.

  • [By ]

    Prior to agreeing to a blockbuster deal with Fujifilm, Xerox Corp. (XRX) received an inquiry from HP Inc. (HPQ) , according to people familiar with the situation, though no formal bid was ever launched.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

  • [By Douglas A. McIntyre]

    A Xerox Corp. (NYSE: XRX) plan to merge with a Japanese company has died. According to Reuters:

    Xerox Corp has scrapped a planned $6.1 billion deal with Fujifilm Holdings Corp in a settlement with activist investors Carl Icahn and Darwin Deason that also hands control of the U.S. photocopier giant to new management.

Hot Blue Chip Stocks To Buy Right Now

Related Watch These 8 Huge Call Purchases In Thursday Trade Benzinga's Option Alert Recap From July 26 Blue Chips, Tech Stocks Advance With Verizon, Facebook Pushing The Pace (Investor’s Business Daily)
Related INTC Regulators Eyeing Amazon's Whole Foods Acquisition Cryptocurrency Mining Is The Next Gold Rush, And AMD To Make Short-Term Gains Selling The 'Pickaxes' Sumitomo Life Insurance Co Buys Intel Corp, Brunswick Corp, VMware Inc, Sells C.R. … (GuruFocus)

Benzinga Pro provides its subscribers with real-time alerts of potentially market-moving options activity.

Here's a recap of the option alerts from Thursday, July 27, 2017. All timestamps are in Eastern Time.

1:31:40 pm: SNAP SNAP Sep 15 $14 Puts at the Bid: 2582 @ $1.861 vs 354 OI; Ref=$13.54

12:00:29 pm: INTC Intel Sep. 2018 $33 Puts Sweep (22) at the Bid: 1076 @ $2.55 vs 138 OI; Ref=$34.967

Hot Blue Chip Stocks To Buy Right Now: StarTek, Inc.(SRT)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the news stories that may have impacted Accern Sentiment’s scoring:

    Get StarTek alerts:

    Startek’s (SRT) CEO Chad Carlson on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) -$0.01 Earnings Per Share Expected for StarTek (SRT) This Quarter (americanbankingnews.com) StarTek (SRT) Downgraded by ValuEngine to Sell (americanbankingnews.com) Zacks: StarTek (SRT) Given $13.50 Consensus Price Target by Analysts (americanbankingnews.com) Edited Transcript of SRT earnings conference call or presentation 8-May-18 8:30pm GMT (finance.yahoo.com)

    StarTek traded down $0.03, hitting $6.98, during trading hours on Friday, according to MarketBeat. The company’s stock had a trading volume of 199,000 shares, compared to its average volume of 114,323. StarTek has a 12 month low of $6.57 and a 12 month high of $14.78. The company has a market capitalization of $108.16 million, a price-to-earnings ratio of -87.25 and a beta of 0.20. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.24 and a current ratio of 2.41.

Hot Blue Chip Stocks To Buy Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Blue Chip Stocks To Buy Right Now: Laredo Petroleum, Inc.(LPI)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
    InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
    Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
    Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
    Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
    LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
    Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
    Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
    Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
    Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
    Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
    The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
    Arcadia Biosciences, Inc. (N

Top Stocks To Watch Right Now

Digital assets roared higher Friday, pushing most major currencies to multiweek highs. After two losing days to begin the week, bitcoin, the No. 1 digital currency, is more than 5% off its Tuesday low and at its highest level since March 26.

Bitcoin
BTCUSD, +3.87%
last changed hands at $8,518.13, up 3%. That move lags the action for other cryptocurrencies, however, as investor appetite for smaller coins grows, with Ripples XRP leading the way. Its up 11.1% to 88 cents.

Top Stocks To Watch Right Now: Astronics Corporation(ATRO)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Astronics (NASDAQ: ATRO) and TransDigm Group (NYSE:TDG) are both aerospace companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

  • [By Ethan Ryder]

    Astronics (NASDAQ: ATRO) and Ducommun (NYSE:DCO) are both small-cap aerospace companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Top Stocks To Watch Right Now: Ebix, Inc.(EBIX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Ebix (NASDAQ:EBIX) issued its earnings results on Wednesday. The technology company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.01), MarketWatch Earnings reports. The business had revenue of $108.23 million for the quarter, compared to analysts’ expectations of $106.81 million. Ebix had a return on equity of 20.67% and a net margin of 27.65%. Ebix’s revenue for the quarter was up 36.8% on a year-over-year basis.

  • [By Shane Hupp]

    Ebix (NASDAQ: EBIX) and Mattersight (NASDAQ:MATR) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

  • [By Shane Hupp]

    ARS Investment Partners LLC boosted its position in shares of Ebix Inc (NASDAQ:EBIX) by 62.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,910 shares of the technology company’s stock after acquiring an additional 35,681 shares during the quarter. ARS Investment Partners LLC owned 0.30% of Ebix worth $6,922,000 at the end of the most recent quarter.

Top Stocks To Watch Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Stocks To Watch Right Now: Principal Financial Group Inc(PFG)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the news articles that may have impacted Accern’s scoring:

    Get Principal Financial Group alerts:

    Principal Financial Group (PFG) Approves New $300M Buyback (streetinsider.com) Principal Financial Group (PFG) Announces Share Repurchase Plan (americanbankingnews.com) Is Principal Large Cap Growth I Institutional (PLGIX) a Strong Mutual Fund Pick Right Now? (finance.yahoo.com) Principal Financial Group is Oversold (nasdaq.com) Principal Names New Chief Human Resources Officer (finance.yahoo.com)

    Several equities analysts have recently commented on PFG shares. Morgan Stanley decreased their target price on Principal Financial Group from $79.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 5th. Wells Fargo reaffirmed a “market perform” rating and issued a $76.00 target price on shares of Principal Financial Group in a research report on Monday, January 8th. Credit Suisse Group started coverage on Principal Financial Group in a research report on Wednesday, April 25th. They issued a “neutral” rating and a $62.00 target price on the stock. Bank of America started coverage on Principal Financial Group in a research report on Monday, March 26th. They issued a “neutral” rating and a $65.00 target price on the stock. Finally, UBS started coverage on Principal Financial Group in a research report on Friday, March 2nd. They issued a “neutral” rating and a $69.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. Principal Financial Group currently has an average rating of “Hold” and an average price target of $71.18.

  • [By WWW.GURUFOCUS.COM]

    For the details of Stilwell Value LLC’s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Stilwell+Value+LLC

    These are the top 5 holdings of Stilwell Value LLCOFG Bancorp (OFG) – 1,614,868 shares, 14.1% of the total portfolio. Kingsway Financial Services Inc (KFS) – 3,780,889 shares, 12.63% of the total portfolio. HopFed Bancorp Inc (HFBC) – 627,128 shares, 7.62% of the total portfolio. Alcentra Capital Corp (ABDC) – 1,251,324 shares, 7.27% of the total portfolio. Shares added by 20.66%Sound Financial Bancorp Inc (SFBC) – 228,600 shares, 7.02% of th

Hot Value Stocks To Watch For 2018

On Wednesday, our Under the Radar Moversnewsletter suggested shorting small cap network equipment stock Ceragon Networks Ltd (NASDAQ: CRNT):

The Ceragon Networks short suggestion is a speculation that today’s bearish outside day can be taken at face value. By “outside day,” we just mean today’s open was above yesterday’s high, and today’s close (so far) is below yesterday’s low. The sudden swing in sentiment is telling, and with CRNT already overbought, it’s not difficult to believe the profit-takers are waiting in the wings. Today’s big swing back to bearishness suggests it’s begun.

Our Under the Radar Moversnewsletter has a detailed discussion about Ceragon Networks technical chart along with a shorting strategy:

Hot Value Stocks To Watch For 2018: Avangrid, Inc.(AGR)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Avangrid Inc.(NYSE:AGR) Q1 2018 Earnings Conference CallApril 23, 2018 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Lisa Levin] Companies Reporting Before The Bell
    Kimberly-Clark Corporation (NYSE: KMB) is expected to report quarterly earnings at $1.71 per share on revenue of $4.60 billion.
    Halliburton Company (NYSE: HAL) is projected to report quarterly earnings at $0.42 per share on revenue of $5.75 billion.
    Lennox International Inc. (NYSE: LII) is estimated to report quarterly earnings at $1.09 per share on revenue of $815.16 million.
    Alaska Air Group, Inc. (NYSE: ALK) is projected to report quarterly loss at $0.12 per share on revenue of $1.82 billion.
    Hasbro, Inc. (NASDAQ: HAS) is expected to report quarterly earnings at $0.35 per share on revenue of $822.15 million.
    Lincoln Electric Holdings, Inc. (NASDAQ: LECO) is projected to report quarterly earnings at $1.08 per share on revenue of $729.83 million.
    Tennant Company (NYSE: TNC) is estimated to report quarterly earnings at $0.15 per share on revenue of $251.93 million.
    FirstEnergy Corp. (NYSE: FE) is projected to report quarterly earnings at $0.67 per share on revenue of $3.43 billion.
    Koninklijke Philips NV (ADR) (NYSE: PHG) is estimated to report earnings for its first quarter.
    Bank of Hawaii Corporation (NYSE: BOH) is expected to report quarterly earnings at $1.23 per share on revenue of $162.39 million.
    Avangrid, Inc. (NYSE: AGR) is projected to report quarterly earnings at $0.79 per share on revenue of $1.72 billion.

     

Hot Value Stocks To Watch For 2018: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Value Stocks To Watch For 2018: The Charles Schwab Corporation(SCHW)

Advisors’ Opinion:

  • [By ]

    Darn hard to not like the numbers out of Action Alerts PLUS holding JPMorgan & Chase (JPM) . Profits up nicely in all segments vs. the fourth quarter. Big year-over-year spikes in return on assets and equity from a year ago. Trading revenue up thanks to the return of volatility in the first quarter (can’t wait to see the blowout quarters from TD Ameritrade (AMTD) and Schwab (SCHW) ). Good card revenue growth from the fourth-quarter bodes well for retailer’s first-quarter results.

  • [By Joseph Griffin]

    TRADEMARK VIOLATION WARNING: “Credit Suisse Group Trims Charles Schwab (SCHW) Target Price to $60.00” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3356662/credit-suisse-group-trims-charles-schwab-schw-target-price-to-60-00.html.

  • [By Shane Hupp]

    Charles Schwab (NYSE:SCHW) had its target price cut by analysts at Credit Suisse Group from $62.00 to $61.00 in a research report issued on Monday. The firm presently has an “outperform” rating on the financial services provider’s stock. Credit Suisse Group’s price target would indicate a potential upside of 10.63% from the company’s current price.

BioCryst Pharmaceuticals (BCRX) Downgraded to Sell at Zacks Investment Research

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

Get BioCryst Pharmaceuticals alerts:

Other equities analysts have also recently issued reports about the stock. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $8.36.

BioCryst Pharmaceuticals traded up $0.28, reaching $5.49, during trading on Friday, according to MarketBeat.com. The company’s stock had a trading volume of 41,176 shares, compared to its average volume of 566,044. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $526.08 million, a P/E ratio of -7.04 and a beta of 2.60. BioCryst Pharmaceuticals has a 12 month low of $5.15 and a 12 month high of $5.52.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.10). The firm had revenue of $3.98 million during the quarter, compared to analyst estimates of $10.20 million. BioCryst Pharmaceuticals had a negative net margin of 392.09% and a negative return on equity of 111.30%. equities analysts expect that BioCryst Pharmaceuticals will post -0.8 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in BCRX. Wells Fargo & Company MN increased its position in BioCryst Pharmaceuticals by 50.7% during the 3rd quarter. Wells Fargo & Company MN now owns 96,671 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 32,530 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock worth $1,678,000 after purchasing an additional 12,267 shares in the last quarter. Alps Advisors Inc. increased its position in BioCryst Pharmaceuticals by 37.7% during the 4th quarter. Alps Advisors Inc. now owns 109,044 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 29,841 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $155,000. Finally, The Manufacturers Life Insurance Company increased its position in BioCryst Pharmaceuticals by 21.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 76,741 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 13,760 shares in the last quarter. Institutional investors and hedge funds own 91.91% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Hot Blue Chip Stocks To Own Right Now

The S&P 500 hit a bottom back in March 2009, spurring on a nine-year bull market. Odds are if you were in the market during this time you made some money, whether it was investing in the indices or equities. 24/7 Wall St. taking a look back to when the S&P 500 bottomed to see how some of the major blue chips have fared since then.

Back on March 6, 2009, the S&P 500 bottomed out at 666.79, and from there began perhaps the biggest bull market of the modern era. At the most recent close, the S&P 500 was at 2,677.67, more than quadrupling its bottom nearly nine years ago.

So how does Intel Corp. (NASDAQ: INTC) measure up?

On an adjusted close basis, Intel closed March 6, 2009, at $9.29 a share, or $12.41 on an unadjusted basis. Intel most recently closed at $47.84 on an adjusted basis.

On the surface, its obvious that Intels growth over this nine-year period outpaced the broad markets. To put some numbers to this, Intel shares gained roughly 415%.So if you had invested $1,000 in Intel back then, you would have $5,149.62 as of Thursdays close.

Hot Blue Chip Stocks To Own Right Now: ANSYS, Inc.(ANSS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

  • [By Shane Hupp]

    Ansys (NASDAQ:ANSS) Director James E. Cashman III sold 862 shares of the firm’s stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $158.00, for a total value of $136,196.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hot Blue Chip Stocks To Own Right Now: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Max Byerly]

    NuStar Energy L.P. (NYSE:NS) declared a quarterly dividend on Friday, April 27th, Wall Street Journal reports. Stockholders of record on Tuesday, May 8th will be paid a dividend of 0.60 per share by the pipeline company on Monday, May 14th. This represents a $2.40 annualized dividend and a dividend yield of 11.49%. The ex-dividend date is Monday, May 7th.

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

Hot Blue Chip Stocks To Own Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Monica Gerson]

    BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 5.98% to $6.91 in the pre-market session after the company has been awarded contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease.

  • [By Sean Williams]

    Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that develops small-molecule drugs to block enzymes involved in disease proliferation, surged as much as 12% today after a report was issued that a highly pathogenic H5N1 bird flu was found in the northern part of Malaysia.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Blue Chip Stocks To Own Right Now: Patheon Holdings Co枚peratief U.A. (PTHN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Thermo Fisher Scientific Inc. (NYSE: TMO) announced plans to acquire Patheon NV (NYSE: PTHN) for $35 per share in cash.

    The deal is projected to complete by the end of 2017.

  • [By Benzinga News Desk]

    In the parched terrain just south of the United States border, the prices of food and other necessities follow the dollar, whose value has been climbing: Link

    ECONOMIC DATA
    Industrial Production (MoM) for Feb 0.00% vs 0.20% consensus estimate; Manufacturing Outputs (MoM) for Feb 0.50% vs 0.40% consensus estimate.
    The University of Michigan's consumer sentiment index for March is schedule for release at 10:00 a.m. ET.
    The index of leading economic indicators for February will be released at 10:00 a.m. ET.
    The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.
    ANALYST RATINGS
    Wunderlich upgraded Adobe Systems (NASDAQ: ADBE) from Hold to Buy
    FBR Capital upgraded L Brands (NYSE: LB) from Market Perform to Outperform
    Morgan Stanley upgraded Dean Foods (NYSE: DF) from Neutral to Overweight
    Baird downgraded Patheon (NYSE: PTHN) from Outperform to Neutral
    Citigroup downgraded SeaWorld Entertainment Inc (NYSE: SEAS) from Neutral to Sell
    Goldman Sachs downgraded Macerich (NYSE: MAC) from Neutral to Sell

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.

  • [By Jon C. Ogg]

    Patheon N.V. (NYSE: PTHN) was downgraded to Neutral from Outperform and the price target was cut to $28 from $34 (versus a $27.72 close, after an 11.7% drop) at Robert W. Baird. Patheon also was downgraded to Sector Weight from Overweight at KeyBanc Capital Markets.

BioCryst Pharmaceuticals (BCRX) Downgraded to Sell at Zacks Investment Research

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

Get BioCryst Pharmaceuticals alerts:

Other equities analysts have also recently issued reports about the stock. ValuEngine upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $8.36.

BioCryst Pharmaceuticals traded up $0.28, reaching $5.49, during trading on Friday, according to MarketBeat.com. The company’s stock had a trading volume of 41,176 shares, compared to its average volume of 566,044. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $526.08 million, a P/E ratio of -7.04 and a beta of 2.60. BioCryst Pharmaceuticals has a 12 month low of $5.15 and a 12 month high of $5.52.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.10). The firm had revenue of $3.98 million during the quarter, compared to analyst estimates of $10.20 million. BioCryst Pharmaceuticals had a negative net margin of 392.09% and a negative return on equity of 111.30%. equities analysts expect that BioCryst Pharmaceuticals will post -0.8 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in BCRX. Wells Fargo & Company MN increased its position in BioCryst Pharmaceuticals by 50.7% during the 3rd quarter. Wells Fargo & Company MN now owns 96,671 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 32,530 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 320,078 shares of the biotechnology company’s stock worth $1,678,000 after purchasing an additional 12,267 shares in the last quarter. Alps Advisors Inc. increased its position in BioCryst Pharmaceuticals by 37.7% during the 4th quarter. Alps Advisors Inc. now owns 109,044 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 29,841 shares in the last quarter. Teacher Retirement System of Texas acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $155,000. Finally, The Manufacturers Life Insurance Company increased its position in BioCryst Pharmaceuticals by 21.8% during the 4th quarter. The Manufacturers Life Insurance Company now owns 76,741 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 13,760 shares in the last quarter. Institutional investors and hedge funds own 91.91% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Hot Medical Stocks To Own Right Now

Inovalon (NASDAQ: INOV) sells its cloud based health care data to health plans and pharmaceutical companies across the United States. The company has data on 139 million members (~42% of the U.S. population) and has data on nearly 12 billion medical events covering nearly 99% of U.S. counties. Inovalon is Samadhi Partners #1 M&A target for 2017.

Inovalon’s client base includes 76% of the top health plans by size and 87% of the top pharmaceutical/life science companies. Inovalon’s cloud database and analytics platform – mainly its MORE2 registry gets smarter the more users it acquires and offers deeper data analytics capabilities. This machine learning technology is how Google came to dominate search. Inovalon’s massive data sets makes it difficult for competitors to compete in the healthcare space. Moreover, Inovalon’s QSI-XL cloud based data analytics platform gets faster the more users it has. Inovalon has nearly 140 million users and its processing speeds are unmatched. Inovalon’s data diagnostics reaches more than 50% of all physicians in the U.S. and accounts for 1.2 billion clinical encounters per year.

Hot Medical Stocks To Own Right Now: Occidental Petroleum Corporation(OXY)

Advisors’ Opinion:

  • [By Chris Lange]

    Occidental Petroleum Corp.s (NYSE: OXY) short interest decreased to 11.44 million shares from the previous reading of 11.77 million. Shares recently traded at $69.65, in a 52-week range of $57.20 to $78.09.

  • [By Paul Ausick]

    Occidental Petroleum Corp. (NYSE: OXY) dropped about 1.6% Friday, to post a new 52-week low of $64.19 after closing at $65.25 on Thursday. The stock’s 52-week high is $78.48. Volume was about 15% below the daily average of around 4.7 million shares. The company had no specific news.

  • [By Michael Flannelly]

    Early on Monday, analysts at Deutsche Bank lowered their price target on Occidental Petroleum Corporation (OXY) to reflect a lower-than-expected valuation of an asset that the oil and gas exploration company is trying to sell.

    Though the analysts lowered OXY’s price target from $114 to $109, they still maintain a “Buy” rating on the stock. The new price target suggests a 22% upside to the stock’s Friday closing price of $89.49.

    Deutsche Bank analyst Paul Sankey said, “Bloomberg Finance LP reports that Oxy is seeking sale of 40% of Mideast operations for around $8bn, which would imply $20bn total value for the unit. However reportedly some suitors are valuing the asset at around $15bn. This is a relatively negative valuation against our previous view that Oxy would be seeking $25+bn for its MENA business. We are cutting our price target to $109/share to reflect this lower implied valuation.”

    Occidental Petroleum shares were up 96 cents, or 1.07%, during pre-market trading on Monday. The stock is up 16.81% year-to-date.

  • [By Ben Levisohn]

    We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the dividend…

  • [By Chris Lange]

    Occidental Petroleum Corp.s (NYSE: OXY) short interest increased to 10.74 million shares from the previous reading of 9.91 million. Shares recently traded at $76.60, in a 52-week range of $57.20 to $78.09.

  • [By Garrett Cook]

    Citi notes that presentations from producers (the bank specifically notes Anadarko (NYSE: APC), Occidental Petroleum (NYSE: OXY), and Pioneer Natural Resources (NYSE: PXD)) showed a lack of commitment to enter 2017 hedge programs to lock in the economics for drilling.

Hot Medical Stocks To Own Right Now: Myers Industries, Inc.(MYE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, basic materials shares fell 0.63 percent. Meanwhile, top losers in the sector included Myers Industries, Inc. (NYSE: MYE), down 7 percent, and CF Industries Holdings, Inc. (NYSE: CF) down 6 percent.

Hot Medical Stocks To Own Right Now: CBRE Clarion Global Real Estate Income Fund(IGR)

Advisors’ Opinion:

  • [By ]

    CBRE Clarion Global Real Estate Income Fund (NYSE: IGR)
    A long time StreetAuthority staple, mainly in the Daily Paycheck portfolio, IGR is considered a core real estate fund. As the “global” in its name implies, the fund takes a broad approach, with just 41% of the fund’s holdings allocated to U.S. REITs. Property-type diversification is also broad with just a 24% allocation to the worrisome retail sector. Shares trade at a nearly 12% discount to their net asset value (NAV) at around $7.80 with a yield approaching 7.7%.

Hot Medical Stocks To Own Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Monica Gerson]

    BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 5.98% to $6.91 in the pre-market session after the company has been awarded contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease.

  • [By Sean Williams]

    Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that develops small-molecule drugs to block enzymes involved in disease proliferation, surged as much as 12% today after a report was issued that a highly pathogenic H5N1 bird flu was found in the northern part of Malaysia.

best stock buys

James and Carrie Finan have been house-hunting in the Seattle area for four months in a seemingly futile race against time: Theyre living in a room in James mothers house and their first child is due in September.

Theyve seen about 40 starterhouses that match their criteria$350,000 or less, three bedrooms, about 1,200 square feet — and made four offers ranging from $32,000 to $82,000 above asking price. Theyve lost out each time.

Every time we hear were not getting it, my heart kind of sinks, James, 29, says. Its been insane.

A big reason the Finans are struggling is the regulatory morass faced by builders like Mike Walsh. On a parcel in Sammamish, Wash., a Seattle suburb, he wouldlike to build 36 relatively affordable houses. But since zoning changes in recent years permit just 25, hell have to sell each at $1.2 million to make the project profitable.

best stock buys: Myriad Genetics, Inc.(MYGN)

Advisors’ Opinion:

  • [By Cory Renauer]

    Shares of Myriad Genetics, Inc. (NASDAQ:MYGN), a DNA diagnostics specialist, dropped 61.4% last year, according todata from S&P Global Market Intelligence.Efforts to offset hereditary cancer-testing segment losses just weren’t successful enough to keep profits, and the stock, from sliding last year.

best stock buys: PowerShares S&P SmallCap Information Technology Portfolio(PSCT)

Advisors’ Opinion:

  • [By ]

    On this chart, I plotted the year-to-date performance of the Nasdaq Composite index against two exchange-traded funds (ETFs) — one is an ETF that tracks the small-cap Russell 2000 index, and the other is PowerShares S&P SmallCap Information Technology Portfolio ETF (Nasdaq: PSCT), which serves as a proxy for the types of small-cap tech stocks that are a focus of my premium newsletter, Game-Changing Stocks.

  • [By ]

    Overall, our Game-Changing Stocks portfolio has had a good run this year. Our closed positions for 2017 have, on average, returned 28.5% — a much stronger result than what we’ve seen from the Russell 2000 index or from the PowerShares S&P Small Cap Information Technology Portfolio ETF (Nasdaq: PSCT), which returned 13% and 11% year-to-date, respectively. It’s not a fair comparison, of course, because our closed positions all have different time frames, but it does stress the strong promise of game-changing stocks.

best stock buys: OneBeacon Insurance Group, Ltd.(OB)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

best stock buys: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Sean Williams]

    Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that develops small-molecule drugs to block enzymes involved in disease proliferation, surged as much as 12% today after a report was issued that a highly pathogenic H5N1 bird flu was found in the northern part of Malaysia.

  • [By Monica Gerson]

    BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 5.98% to $6.91 in the pre-market session after the company has been awarded contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease.

best stock buys: Lifetime Brands Inc.(LCUT)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Monday, cyclical consumer goods & services shares gained by 0.41 percent. Top gainers in the sector included Kandi Technologies Group Inc (NASDAQ: KNDI), Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT), and Lifetime Brands Inc (NASDAQ: LCUT).

best stock buys: Paragon Offshore plc (PGNPQ)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Paragon Offshore’s (OTCPK:PGNPQ) former management’s audacious efforts to omit parts of the senior secured lenders by deeming them unimpaired and instead pay out the majority of the company’s cash to junior unsecured bondholders by presenting a set of entirely unrealistic business forecasts to the court. Fortunately, in case of Paragon Offshore, the bankruptcy judge recognized the framing and accordingly denied confirmation of the company’s plan of reorganization, effectively sending Paragon Offshore back to the drawing board. Consequently, management was ousted after the failure. I have covered the Paragon Offshore saga in a series of articles over the past few quarters, so interested investors might want to take a look at this highly fascinating and still evolving case study.

  • [By SEEKINGALPHA.COM]

    With even brand new rigs struggling to find work, the jig was soon up for owners of old equipment, like Paragon Offshore (OTCPK:PGNPQ), which is currently undergoing its second debt restructuring in less than three years of independent existence. Likewise, drillers with a fondness for aggressive use of debt were soon in trouble, most notably, former high-flier Seadrill (SDRL) and its little brother North Atlantic Drilling (NADL), which will no doubt file for restructuring within months. As a consequence of the crisis, the OSD industry now has a number of participants without a large debt burden, either new entrants like Borr Drilling, or established competitors that have had debt reduced in a restructuring, such as Ocean Rig (ORIG), to be followed within this year by others, almost certainly including each of SDRL, NADL, and Pacific Drilling (PACD).

Top 10 Gas Utility Companies To Invest In Right Now

The S&P 500 this week suffered its biggest drop in two months as investors fretted about the strength of the economy as earnings season approaches.

Associated Press

The S&P 500 fell 1.2% to2,047.60 this week–its worst decline since the week ending Fe. 5–after rising 0.3% today. The Dow Jones Industrial Average dropped 1.2% to17,576.96 this week after advancing 35 points, or 0.2%, today. The Nasdaq Composite declined 1.3% to 4,850.69 this week after finishing little changed today.

Gluskin Sheff’s David Rosenberg worries that the market is headed for another correction:

It looks very likely that we are entering into another corrective phase for the equity markets. The bounce off the February 11th low has played out and the various factors that propelled risk appetite at the time are now fully priced in and then some.

Top 10 Gas Utility Companies To Invest In Right Now: CA Inc.(CA)

CA Technologies, together with its subsidiaries, designs, develops, markets, delivers, licenses, and supports information technology (IT) management software products that operate on a range of hardware platforms and operating systems. It offers enterprise IT management software for organizations that addresses components of the computing environment, including people, information, processes, systems, networks, applications, and databases. The company provides a portfolio of mainframe and distributed software products with a focus on mainframe, service assurance, security (identity and access management), project and portfolio management, service management, virtualization and service automation, and cloud computing. It serves banks, insurance companies, other financial services providers, government agencies, manufacturers, technology companies, retailers, educational organizations, and health care institutions worldwide. CA Technologies offers its solutions through its d irect sales force and indirectly through global systems integrators, technology partners, managed service providers, solution providers, distributors and volume partners, and exclusive representatives. The company was formerly known as CA, Inc. and changed its name to CA Technologies in May 2010. CA Technologies was founded in 1974 and is based in Islandia, New York.

Advisors’ Opinion:

  • [By Jonas Elmerraji]

    The chart of CA (CA) doesn’t need much introduction — it’s about as simple as a technical pattern gets. CA is currently bouncing higher in an uptrending channel, a setup that gives us a very high probability range for shares of CA to remain within. Here’s how to trade it.

    Trendline support is the price level to watch right now in CA — it’s been the floor that’s kept CA bouncing higher each of the last five times it’s been tested. Even though it generally makes sense to be a buyer anywhere in an uptrend, the ideal time to buy comes on a bounce off of support.

    Buying off a support bounce makes sense for two big reasons: It’s the spot where shares have the furthest to move up before they hit resistance, and it’s the spot where the risk is the least (because shares have the least room to move lower before you know you’re wrong). With little room between the trendline support line and CA’s most recent price, this week looks like as good a time as any to start building a position.

Top 10 Gas Utility Companies To Invest In Right Now: BioCryst Pharmaceuticals Inc.(BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer to develop new therapeutic candidates. The company has three novel late-stage compounds in development, which include Peramivir, a neuraminidase inhibitor for the potential treatment of influenza; BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for gout; and Forodesine, a PNP inhibitor for cutaneous T-cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services. Forodesine has been granted orphan drug status by the FDA for thr ee indications, which include T-cell non-Hodgkin?s lymphoma, including CTCL; CLL and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-ALL. The FDA has also granted fast track status to the development of forodesine for the treatment of relapsed or refractory T-cell leukemia, and special protocol assessment from the FDA for forodesine to conduct a pivotal clinical trial in CTCL with an oral formulation. The company announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone. BioCryst Pharmaceuticals utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The company was founded in 1986 and is headquartered in Durham, North Carolina.

Advisors’ Opinion:

  • [By Monica Gerson]

    BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 5.98% to $6.91 in the pre-market session after the company has been awarded contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease.

Hot Up And Coming Stocks To Own Right Now: Intrexon Corporation(XON)

 

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Janssen Pharmaceutica NV; and strategic coll aboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Overvalued companies include MWI Veterinary (MWIV) andStericycle (SRCL), while companies with attractive valuations include Cardinal Health (CAH), Selected Medical (SEM). He’s not a fan of Intrexon (XON) but callsAratana (PETX) a “hidden gem.”

Top 10 Gas Utility Companies To Invest In Right Now: Transcananda Pipelines Ltd.(TRP)

Transcanada Corporation operates as an energy infrastructure company in North America. The company operates in three segments: Natural Gas Pipelines, Oil Pipelines, and Energy. The Natural Gas Pipelines segment develops and operates energy infrastructure, including natural gas pipelines and regulated gas storage facilities. Its network of natural gas pipelines extends approximately 60,000 km tapping into gas supply basins in North America. The Oil Pipelines segment operates Keystone crude oil pipeline system, which includes completed 3,467 km Wood River/Patoka and Cushing Extension phases, and the proposed 2,673 km U.S. Gulf Coast Expansion. The Energy segment engages in the acquisition, development, construction, ownership, and operation of electrical power generation plants; the purchase and marketing of electricity; the provision of electricity account services to energy and industrial customers; and the development, construction, ownership, and operation of non-regulat ed natural gas storage in Alberta. The company was founded in 1951 and is headquartered in Calgary, Canada.

Advisors’ Opinion:

  • [By Chad Tracy]

    The most obvious is TransCanada (NYSE: TRP), the company that has submitted the proposal for the expansion. 

    TransCanada's cash flow is derived from natural gas (62%), oil/liquids (16%), and energy (22%), which includes natural gas storage.

Top 10 Gas Utility Companies To Invest In Right Now: Frontier Communications Corporation(FTR)

 

Frontier Communications Corporation, a communications company, provides regulated and unregulated voice, data, and video services to residential, business, and wholesale customers in the United States. The company offers residential services, such as fiber-to-the-home and fiber-to-the-node broadband, video, and voice over Internet protocol products, as well as traditional copper-based broadband products; and commercial services, including Ethernet, dedicated Internet, multiprotocol label switching, time division multiplexing, data transport services, and optical transport services. It also provides Frontier Secure suite of products for computer security, cloud backup and sharing, identity protection, equipment insurance, and technical support; unified messaging services comprising call forwarding, conference calling, caller identification, voicemail, and call waiting services; long distance network services; and packages of co mmunications services. In addition, the company offers switched access services that facilitate other carriers to use the companys facilities to originate and terminate their local and long distance voice traffic; satellite TV video services; a range of third-party communications equipment to small, medium, and enterprise business customers; and directories. As of December 31, 2014, it had approximately 3,214,800 residential customers; approximately 304,700 business customers; 2,373,900 broadband subscribers; and 586,600 video subscribers. The company was formerly known as Citizens Communications Company and changed its name to Frontier Communications Corporation in July 2008. Frontier Communications Corporation was founded in 1927 and is based in Norwalk, Connecticut.

Advisors’ Opinion:

  • [By WilliamBriat]

    Frontier Communications Corporation (NASDAQ: FTR) provides phone, Internet, and satellite TV (through a partnership with DISH Network) services to more than 25 states. The company provides an annual dividend of 9.3% and reaffirmed its full-year guidance.

Top 10 Gas Utility Companies To Invest In Right Now: Oaktree Capital Group, LLC(OAK)

 

Oaktree Capital Group, LLC operates as a global investment management firm that focuses on alternative markets. It manage investments in a number of strategies within six asset classes, including distressed debt; corporate debt, including high yield debt and senior loans; control investing; convertible securities; real estate; and listed equities. The company pursues these strategies through closed-end, open-end, and evergreen funds. Oaktree Capital Group, LLC was founded in 1995 and is headquartered in Los Angeles, California.

Advisors’ Opinion:

  • [By Igor Greenwald, Financial Columnist, The Energy Strategist]

    Oaktree Capital Group (OAK) raises most of the funds it invests in companies, credit, and real estate from institutional investorsincluding public pension fundsand charges them hedge-like fees for the privilege.

Top 10 Gas Utility Companies To Invest In Right Now: Credit Suisse Group(CS)

Credit Suisse Group AG, together with its subsidiaries, operates as a financial services company. The company operates in three segments: Private Banking, Investment Banking, and Asset Management. The Private Banking segment offers advisory services and a range of wealth management solutions, including pension planning, life insurance products, tax planning, and wealth and inheritance advice for the high-net-worth and ultra-high-net-worth individuals. This segment also supplies banking products and services to affluent, high-net-worth and ultra-high-net-worth clients, and corporates and institutions. The Investment Banking segment provides investment banking and securities products and services to corporations, governments, pension funds, and institutions. Its products and services include debt and equity underwriting, sales and trading, mergers and acquisitions advice, divestitures, corporate sales, restructuring, and investment research. The Asset Management segment offe rs integrated investment solutions and services to institutions, governments, foundations and endowments, corporations, and individuals. It provides access to a range of investment classes across alternative investment, asset allocation, and traditional investment strategies. The company operates in Switzerland, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. Credit Suisse Group AG was founded in 1856 and is headquartered in Zurich, Switzerland.

Advisors’ Opinion:

  • [By Wayne Duggan] Related DB Deutsche Bank In The Tank Mike Khouw Sees Unusual Options Activity In Deutsche Bank 33 Large Banks On The Federal Reserve's Radar In 2016 (Seeking Alpha) Related CS Earnings Scheduled For February 4, 2016 Blockchain Moves Forward In The Financial Industry Credit Suisse Group AG (CS) Tidjane Thiam on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    The latest credit default swap (CDS) data from BMO Capital Markets indicate a number of investors are growing increasingly concerned about the one-year outlook for capital markets. In a new report, analyst Mark Steele discussed the recent surge in one-year CDS activity, and what it means for the market.

  • [By Paul R. La Monica]

    European banks worse off than 2008? Lamensdorf is concerned about the exposure to bad loans (especially energy company debt) held by big banks such as Royal Bank of Scotland (RBS), Credit Suisse (CS) and Deutsche Bank (DB). He’s shorting all three.

Top 10 Gas Utility Companies To Invest In Right Now: Williams-Sonoma Inc.(WSM)

Williams-Sonoma, Inc. operates as a specialty retailer of home products. It offers culinary and serving equipment, including cookware, cookbooks, cutlery, informal dinnerware, glassware, table linens, specialty foods, and cooking ingredients; and bridal and gift items under the Williams-Sonoma brand name. The company also provides home furnishing categories, including furniture, textiles, decorative accessories, lighting, and tabletop items under the West Elm brand name; bed and bath products under the Pottery Barn brand name; and children?s furnishings and accessories under the Pottery Barn Kids brand name. Williams-Sonoma, Inc. sells its home products through four retail store concepts, which include Williams-Sonoma, Pottery Barn, Pottery Barn Kids, and West Elm; six direct-mail catalogs that comprise Williams-Sonoma, Pottery Barn, Pottery Barn Kids, Pottery Barn Bed and Bath, PBteen, and West Elm; and six e-commerce Websites, which consist of williams-sonoma.com, potte rybarn.com, potterybarnkids.com, pbteen.com, westelm.com, and wshome.com. As of January 30, 2011, it operated 592 stores, including 260 Williams-Sonoma, 193 Pottery Barn, 85 Pottery Barn Kids, 36 West Elm, and 18 outlet stores located in 44 states of the United States; Washington, D.C.; Canada; and Puerto Rico. The company was founded in 1956 and is headquartered in San Francisco, California.

Advisors’ Opinion:

  • [By Monica Gerson]

    Wall Street expects Williams-Sonoma, Inc. (NYSE: WSM) to post its quarterly earnings at $1.58 per share on revenue of $1.62 billion. Williams-Sonoma shares declined 0.14 percent to $58.13 in after-hours trading.

  • [By Monica Gerson]

    Williams-Sonoma, Inc. (NYSE: WSM) is projected to post its quarterly earnings at $1.58 per share on revenue of $1.62 billion.

    CLARCOR Inc. (NYSE: CLC) is estimated to post its quarterly earnings at $0.40 per share on revenue of $310.87 million.

Top 10 Gas Utility Companies To Invest In Right Now: Wendy’s/Arby’s Group Inc.(WEN)

The Wendy’s Company operates as a quick-service hamburger company in the United States. The company, through its subsidiary, Wendy’s International, Inc., operates as a franchisor of the Wendy’s restaurant system. As of December 26, 2011, the Wendy’s system comprised approximately 6,500 franchise and company restaurants in the United States and the United States territories, as well as in 26 other countries worldwide. The company was formerly known as Wendy’s/Arby’s Group, Inc. and changed its name to The Wendy’s Company in July 2011. The Wendy’s Company was founded in 1884 and is headquartered in Dublin, Ohio.

Advisors’ Opinion:

  • [By Jim Jubak, Senior Markets Editor, MoneyShow.com]

    It’s hard for any company to raise prices in the current non-inflationary environment. But it’s especially hard right now for operators of fast food restaurants, given the intense price competition in a very crowded marketplace. McDonald’s sales growth in recent quarters has been driven by the success of its Dollar Menu, so raising prices in that segment are a big deal for the company. In addition, pushback from franchisees who say they can’t afford to refurbish their stores, given higher charges from McDonald’s hits at one of McDonald’s key advantages in its market—it’s ability to refresh stores more frequently than competitors. A McDonald’s refresh at $600,000 on average, according to the company, costs substantially more than a remodel at Burger King (BKW) at $300,000 or Wendy’s (WEN) at $375,000 for the least expensive version. McDonald’s restaurants average $2.5 million in annual sales.

  • [By Michael Flannelly]

    Argus Research upgraded fast food restaurant operator The Wendy’s Co (WEN) on Thursday, noting that the company’s store remodeling and new menus should help drive higher sales.

    The analysts upgraded WEN from “Hold” to “Buy” and see shares reaching $10. This price target suggests a 21% upside to the stock’s Wednesday closing price of $8.25.

    Wendy’s shares were up 24 cents, or 2.91%, during early morning trading on Thursday. The stock is up 54.19% year-to-date.

Top 10 Gas Utility Companies To Invest In Right Now: Nu Skin Enterprises Inc.(NUS)

Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements worldwide. The company sells its personal care products under the Nu Skin brand; and nutritional supplements under the Pharmanex brand. Its personal care product line includes core systems, targeted treatments, total care, cosmetic, and Epoch, a product formulated with botanical ingredients. The company?s nutritional supplements product line comprises micronutrient supplements, targeted solution supplements, and weight management products. It also sells Vitameal, which are nutritious meal products for starving children or purchased for personal food storage. In addition, the company offers other products and services consisting of digital content storage, water purifiers, and other household products. It sells its products primarily through a network of independent distributors in north Asia, the Americas, Greater China, Europe, and the south Asia/Pacific. The c ompany also operates retail stores to sell its products in China. As of December 31, 2010, Nu Skin Enterprises operated 40 stores throughout China. The company was founded in 1984 and is headquartered in Provo, Utah.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.